Equativ and Titan OS Partner to Revolutionize CTV Advertising with Retail Media Precision
LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Equativ today announces it has become the new ad server and primary supply-side platform (SSP) for Titan OS, the European technology and advertising company that has developed an independent Operating System for Connected TV (CTV). The partnership brings the power of retail media to CTV, enabling brands to deliver highly targeted, outcome-driven campaigns.
Launched in 2024, Titan OS has established a unified ecosystem and secured agreements with TV manufacturers, content providers, retailers, and advertisers, reaching 30 million homes across Europe. Its operating system runs on millions of Philips TVs, and will soon run on JVC TVs. On the content side, it offers a selection of premium streaming channels on Sony's Android TVs.Aligning seamlessly with Equativ's vision for growth in the CTV and retail media ecosystem, media buyers can now take advantage of new opportunities, including:
Premium media placements: Access to premium media placements, including full-screen homepage takeovers and in-stream visibility on more than 50 leading free ad-supported streaming TV (FAST) channels, such as CNN, FIFA+, Euronews, Bloomberg, Sony One, and the Hearst Media portfolio of channels.
High-impact creative formats: Unique CTV creative enhancements and innovative formats, designed to maximise user attention and performance. Launching in 2025, shoppable ad formats will combine retail data and Equativ ad tech.
Advanced CTV targeting: Gain valuable insights into audience viewing behaviour and deliver highly targeted campaigns by leveraging first-party data and advanced technologies, such as machine learning and AI models used to create precise audience segments, and Automatic Content Recognition (ACR) to identify content consumption, ad views on local apps, and the use of peripherals like game consoles.
Retail audience extension: Refined audience segments created by combining Titan's first party with first-party data from partnerships with top retailers in a safe and privacy-first environment. This enables advertisers to reach potential buyers at key decision-making moments on big screens.
Teiffyon Parry, Chief Strategy Officer at Equativ, commented: 'CTV is one of the fastest-growing advertising channels, and when combined with retail media's powerful first-party data, it creates an unmatched opportunity for brands to connect with targeted consumers at the right moment. Our new partnership with Titan OS builds on this momentum, allowing us to offer media buyers premium inventory and exclusive retail data, maximising the effectiveness of their CTV campaigns following the marketing funnel. After the alliance with Deutsche Telekom last year, this new strategic partnership represents a significant stride in evolving our programmatic TV advertising services across Europe and continued expansion into the US.'
Joe Evea, SVP Advertising and Retail Media, at Titan OS, added: 'We are excited about the opportunities this partnership unlocks at the intersection of retail media and CTV. It will allow us to support retailers to increase their retail media revenues, giving them access to CTV inventory across 30 million households. Retailers' first-party data becomes key to improving targeting capabilities, and this partnership with Equativ will give us access to unique shoppable ad formats to drive conversion on CTV. After our first partnership with Currys in the UK, we plan to partner with a few more strategic retailers across Europe during 2025.'
To learn more about Equativ's expansion and programmatic solutions, visit Equativ.com.
For media inquiries, please contact: Caroline Millié Figueiredo at: pr@equativ.com.
About Equativ
Equativ, a leading independent ad platform, brings scale and simplicity to digital advertising. Following its recent merger with Sharethrough and the acquisition of Kamino Retail, advertisers, media owners, and technology partners rely on Equativ's advanced SSP, curation, and retail media services and technology to achieve maximum business outcomes. With a focus on privacy-first programmatic video, CTV, and data-driven solutions, Equativ enables clients to activate across the digital ecosystem while protecting consumer privacy. The company's global expertise is also backed by a team of over 750 employees across 19 countries. Learn more at Equativ.com.
About Titan OS S.L.Titan OS S.L. is a technology company headquartered in Barcelona, with branches in Amsterdam and Taipei. It specializes in developing software and solutions to unleash the full potential of Connected TV. It is rethinking TV to change the way people discover content and how brands connect with audiences, making content discovery easier. Its aim is to foster collaborations across the entire TV ecosystem to grow business together with TV manufacturers, retailers, media companies, content creators, publishers, and brands. Its independent operating system powers smart TV devices from world-class manufacturers across Europe and Latin America, offering millions of viewers a personalized experience from the moment they switch on their TVs. With tailored recommendations, it seamlessly integrates all content on the homepage, from streaming subscription services, free and paid movies, series, and TV shows to linear channels. www.titanos.tv
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8c282cdd-cfde-4e92-93ee-b9723a6082b8Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Editorial: Leave Airbnbs and short-term rentals alone, aldermen. There's no crisis here.
Nobody loves killing Airbnbs more than hoteliers. After New York City moved in 2022 to sharply restrict short-term rentals by enacting something called Local Law 18, hotel rates went through the roof. Last September, it cost an average of $417 to spend the night in Manhattan. And, typically, that's for one small room; however many kids you might have along with you. Although it was passed on the grounds of promoting safety and equity, Local Law 18 ended up making it nearly impossible for a regular person to rent out their Manhattan place on a short-term basis unless they were themselves present in their apartment with the guests. The vast majority of short-term listings quickly vanished, much to chagrin of ordinary working people who had used Airbnb to rent out their homes when they were out of town for work or to help offset their massive residential rent during times of increased demand such as major conventions or sporting events. It also explains why, if you try and get an Airbnb in New York, the host will probably say that they will be at least kinda present, so as to conform with the law. Not that anyone wants that. Airbnbs can indeed be a problem in certain hugely popular destinations. Travel writer Rick Steves has described the situation in some European tourist hubs where local people get priced out of a central city and landlords rent only to tourists. Thus, instead of visiting a vibrant community with local shops and bakeries, tourists are met instead with other tourists and tchotchke stores. And an argument can be made that short-term rentals add to the pressure on longer-term rents by reducing supply, although that is a contested argument in most cities because such rentals also encourage new construction. Short-term rentals also allow visitors to avoid costly hotel rates and have room to spread out. They are rented by people who then walk into local restaurants and businesses and buy stuff or attend live entertainment offerings. Airbnbs tend to draw visitors out of the downtown core and into less affluent neighborhoods, spreading the economic pie beyond the central business district and letting families, especially, save some money and get to know the real heart of a city. In Chicago, for example, there are relatively few hotels outside the center of the city; if you are a jazz fan and want to stay close to the Green Mill, for example, an Airbnb in Uptown would offer you real benefits and you might end up staying longer, or even moving here altogether. We don't see any evidence of Chicago having some massive Airbnb problem; this is a city that needs to expand its tourist base, not suppress it by killing Airbnbs. We know of few buildings that have been taken over by short-term rentals and we note that large buildings can already restrict such rentals on their own, using existing condo regulations, if they so choose. For sure, there's a danger of people holding parties in these places or using them to drink underage. But some people also behave badly in hotel rooms and private residences. Laws are on the books that can be enforced without preventing the rentals in the first place, and we have no problem with a registration procedure that can help police see if a rental is proving to be a repeat problem. Chicago has many protections in place. If 25% of a precinct's registered voters want to ban short-term rentals and sign a petition, they can do so now. So we see no need whatsoever for the over-reaching ordinance championed by Ald. Anthony Napolitano, 41st, and approved by the Committee on License and Consumer Protection that would give aldermen the power to outright ban Airbnbs by aldermanic fiat and then force Airbnb and its competitors to collect signatures to overturn the ban and stay in business. Imagine if that was proposed for restaurants or hotels! In practice, this would be a field day for NIMBY types (or sly hotel owners) who have an alderman's ear (or the means to boost an aldermanic bank account). In practice, it would mean that short-term rentals would likely disappear all over the city, reducing the side hustles of lots of cash-strapped folks, hurting local businesses, reducing city and state tax revenues and meaning that visitors would have no choice but to stuff themselves and their kids into costly hotel rooms instead of being able to stay where most Chicagoans live. City Council should leave this well alone. If and when the city is overwhelmed with tourists, we're happy to revisit our view. But at this cash-strapped juncture for the city of Chicago, Napolitano's power move should be voted down. Submit a letter, of no more than 400 words, to the editor here or email letters@
Yahoo
38 minutes ago
- Yahoo
7.6% CAGR Predicted as Demand for Lightweight Vehicle Solutions Rises
The Global Carbon Fiber in Automotive Application Market is set to grow from USD 6.18 billion in 2025 to USD 10.34 billion by 2032, driven by a 7.6% CAGR. This growth is powered by demand for lightweight, high-performance materials that enhance vehicle efficiency, especially as EV adoption rises. Carbon Fiber in Automotive Application Market Dublin, June 13, 2025 (GLOBE NEWSWIRE) -- The "Carbon Fiber in Automotive Application Market Size, Share, Trends, Analysis, and Forecast 2025-2034 | Global Industry Growth, Competitive Landscape, Opportunities, and Challenges" has been added to offering. The Global Carbon Fiber in Automotive Application Market, valued at USD 6.18 billion in 2025, is projected to achieve a notable CAGR of 7.6%, reaching USD 10.34 billion by 2034 The research report provides in-depth market insights for global and regional sectors, helping stakeholders uncover new market opportunities, manage competition, and strategize investments. The data covers key players, market forecasts, geopolitical impacts, and technological developments, making it a valuable resource for top management, investors, and product developers in the automotive industry. This market focuses on the use of lightweight, high-strength materials to boost vehicle performance, fuel efficiency, and sustainability. Carbon fiber stands out due to its low density, exceptional tensile strength, and corrosion resistance, making it ideal for applications ranging from body panels to interior parts. The shift towards electric vehicles (EVs) and more stringent fuel economy standards are propelling the demand for carbon fiber. Its capacity to reduce vehicle weight enhances handling, acceleration, and battery range in EVs. Furthermore, its superior strength-to-weight ratio contributes to improved safety and durability, particularly desirable for premium and high-performance vehicles. In 2024, the market experiences considerable growth driven by consumer demand for fuel-efficient, eco-friendly vehicles. North America and Europe are leading, thanks to advanced manufacturing and strong environmental regulations, while Asia-Pacific emerges as a significant player due to its expanding automotive production and emphasis on lightweight EV materials. Key takeaways include the importance of carbon fiber's lightweight and high-strength properties, its application in multiple vehicle components, and the regional leadership of North America and Europe. The Asia-Pacific region is rapidly growing, poised to play a crucial role. The rise of EVs and fuel economy standards accelerates the demand for carbon fiber, despite challenges such as high costs and limited production scalability. Manufacturers are focusing on R&D for cost-effective and innovative solutions, promoting wider adoption beyond luxury cars into mass-market vehicles. Collaboration between automotive OEMs and material suppliers is fostering new applications. The market segmentation by type includes polyacrylonitrile, pitch, and rayon-based fibers; by application-body structure, interior components, chassis, and drive shafts. The segmentation extends to end-users, technology, distribution channels, and global regions. The market analysis covers trends, driving factors, challenges, trade and price analysis, and the competitive landscape. Industry stakeholders can benefit from detailed sales data, market analysis, trends, and competitive insights, aiding in strategic planning and risk mitigation. Customization options are available to cater to specific research needs, allowing tailored market division, substantial analysis, and investment insights. Key Attributes: Report Attribute Details No. of Pages 150 Forecast Period 2025 - 2034 Estimated Market Value (USD) in 2025 $6.18 Billion Forecasted Market Value (USD) by 2034 $11.95 Billion Compound Annual Growth Rate 7.6% Regions Covered Global Companies Featured Toray Industries, Inc. Hexcel Corporation SGL Carbon SE Mitsubishi Chemical Corporation Teijin Limited Solvay DowAksa Formosa Plastics Corporation Hyosung Corporation Cytec Industries Toho Tenax Co., Ltd. Gurit Zoltek Corporation Plasan Carbon Composites Chomarat For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Carbon Fiber in Automotive Application Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
38 minutes ago
- Yahoo
Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025
New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib REDWOOD CITY, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ('Biomea' or the 'Company') (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced updated preliminary clinical data from the ongoing Phase I COVALENT-103 trial of BMF-500 in adults with relapsed or refractory ('R/R') acute leukemia ('AL'). The results will be presented in a poster presentation at the European Hematology Association ('EHA') 2025 Congress in Milan, Italy. The presentation by Dr. Farhad Ravandi of The University of Texas MD Anderson Cancer Center will highlight emerging safety, pharmacokinetics/pharmacodynamics, and early clinical activity data for BMF-500, a highly selective covalent FMS-like tyrosine kinase 3 ('FLT3') inhibitor, in heavily pretreated patients with R/R AL. Key Results from the EHA 2025 Poster Presentation27 patients were enrolled across two study arms, Arm A (no CYP3A4 inhibitor; n=10) and Arm B (CYP3A4 inhibitor; n=17). All patients had R/R AL, with a median of 4 prior lines of therapy. 18 of the 27 patients were FLT3 mutations ('FLT3m') while the other 9 patients had FLT3 wild-type AL. Frequent co-mutations included WT1, TP53, IDH1/2, and NRAS. All 18 FLT3m patients had failed gilteritinib in the R/R setting and 9 of the 18 had received at least two FLT3 inhibitors prior to study entry. 26 of 27 (96%) enrolled patients had also received and failed the BCL2 inhibitor venetoclax. Key findings include: Clinical Activity Observed: 9 of 11 efficacy-evaluable FLT3m patients, defined as all patients enrolled who received at least one dose and had at least one disease assessment, showed bone marrow (BM) blast reduction; 5 of 11 achieved >50% BM blast reduction. 1 FLT3m patient achieved complete remission with incomplete hematologic recovery (CRi), sustained for 6 cycles. 1 FLT3m patient achieved morphologic leukemia-free state (MLFS); response is ongoing. 1 FLT3m patient met all criteria for partial response (PR) except platelet recovery; categorized as near PR. 2 of 4 efficacy-evaluable FLT3 wild-type patients achieved durable disease control ≥120 days, with treatment ongoing for one patient. Additional clinical improvements include reductions in peripheral blasts, transfusion dependency, and frequency of hydroxyurea use. Pharmacokinetics/Pharmacodynamics: FLT3 inhibition correlated with BMF-500 systemic exposures. Bone marrow and plasma concentrations of BMF-500 and its metabolites were comparable, suggesting good compartmental penetration. Survival: Median overall survival (mOS) among all treated FLT3m patients (n=18) was 3.8 months (Arm A) and 3.5 months (Arm B) during dose escalation. For the efficacy-evaluable FLT3m patients (n=12), the mOS for Arms A and B was 3.8 and 3.6 months, respectively during dose escalation. These survival durations compare favorably to historical mOS of 2.1 months in patients with R/R FLT3m acute myeloid leukemia ('AML') post-failure with both gilteritinib and venetoclax. 1 Ongoing Dose Escalation: Dose escalation continues at 200 mg BID (Arm A) and 75 mg BID (Arm B). Based on observed activity and tolerability, further evaluation is underway to determine optimal biologic dose ('OBD') and recommended Phase II dose ('RP2D'). Safety and Tolerability BMF-500 was generally well-tolerated across dose levels. No dose-limiting toxicities (DLTs), QT prolongation, or discontinuations due to treatment-related adverse events were reported. Escalation is ongoing without safety restrictions. 'The updated COVALENT-103 results continue to support the potential of BMF-500 as a selective, covalent FLT3 inhibitor,' said Mick Hitchcock, Ph.D., Interim Chief Executive Officer of Biomea Fusion. 'We are encouraged by the depth of bone marrow responses, the achievement of MLFS and CRi, and the early survival benefit in heavily pretreated patients with FLT3 mutations who had progressed following prior FLT3 inhibitor therapy. These data speak to BMF-500's potential to meaningfully improve outcomes in a high-risk AML population with no currently available treatment options.' Following completion of the COVALENT-103 dose escalation phase in R/R AL patients with FLT3m, Biomea plans to conclude its internal development of BMF-500 in oncology and is actively exploring strategic partnerships to advance the program. Poster Presentation Details Date/Time: Saturday, June 14 (18:30-19:30 CEST) Title: Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the COVALENT-103 Study (NCT05918692) Poster Number: PS1520 Presenter: Farhad Ravandi, M.D., University of Texas MD Anderson Cancer Center About COVALENT-103 COVALENT-103 is a multicenter, open-label, non-randomized trial seeking to evaluate the safety and efficacy of BMF-500, a twice daily oral treatment, in adult patients with R/R AL with FLT3 wild-type or FLT3m. The Phase I COVALENT-103 study aims to evaluate the safety and tolerability of BMF-500, determine the optimal biologic dose and recommended Phase II dose, and identify initial efficacy signals. Additional information about the Phase I clinical trial of BMF-500 can be found at using the identifier, NCT05918692. About BMF-500 BMF-500 is an investigational, orally bioavailable, covalent small molecule inhibitor of FLT3, discovered in-house using Biomea's proprietary FUSION™ System. Designed to be highly potent and selective, BMF-500 has demonstrated encouraging potential in extensive preclinical studies. Its kinase inhibitory profile indicates strong target selectivity, which may translate to a reduced risk of off-target effects. About Biomea FusionBiomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650, both designed to significantly improve the lives of patients with diabetes, obesity, and other metabolic diseases. We aim to cure. Visit us at and follow us on LinkedIn, X, and Facebook. Forward-Looking Statements Statements we make in this press release may include statements which are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'). These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will,' and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact, including statements regarding the clinical and therapeutic potential of our product candidates and development programs, including BMF-500, the potential of BMF-500 as a treatment for patients with FLT3m R/R AL, our research, development, partnership and regulatory plans, and the timing of such events may be deemed to be forward-looking statements. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. Any forward-looking statements in this press release are based on our current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including the risk that preliminary or interim results of preclinical studies or clinical trials may not be predictive of future or final results in connection with future clinical trials and the risk that we may encounter delays in preclinical or clinical development, patient enrollment and in the initiation, conduct and completion of our ongoing and planned clinical trials and other research and development activities. These risks concerning Biomea's business and operations are described in additional detail in its periodic filings with the U.S. Securities and Exchange Commission (SEC), including its most recent periodic report filed with the SEC and subsequent filings thereafter. Biomea Fusion explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Reference: 1. Corley et al. (P1798) HemaSphere 2024;8(S1), 3339-3340. Contact: Meichiel Jennifer Weiss Sr. Director, Investor Relations and Corporate DevelopmentIR@
